Conjugate vaccines: An important market for addressing infectious diseases

Conjugate vaccines, which prevent bacterial infections in humans, is experiencing significant demand and market growth. A conjugate vaccine contains bacterial capsular polysaccharide joined to a protein to enhance immunogenicity and protect against invasive diseases. They are the most effective forms of immunization, used to prevent diseases in both infants and adults.  The rising incidents of pneumococcal pneumonia in adults, improving vaccine manufacturing processes, coupled with the major vaccination initiatives taken by governments, are some of the key factors driving growth in the global conjugate vaccine market.

Here’s a quick overview of the conjugate vaccine market, based on Netscribes market research.

Conjugate vaccine market 2018

For a detailed market and competitive analysis of conjugate vaccines by indication, age, country, and more, contact

Pan American Health Organization (PAHO)

PAHO has undertaken to make sustainable and affordable national health programs, encouraging improvements in availability and quality of vaccines from both private and public sectors. PAHO is committed to continuing collaboration with DCVMn (The Developing Countries Vaccine Manufacturers’ Network) members and welcome innovative suggestions, to ensure that the Americas have sustainable access to life-saving vaccines. Deputy Director from PAHO, outlined achievements of public health goals in the Americas, including an extension of the reach of national immunization programs, new vaccine introductions, strengthening of regulatory pathways and improving financing and forecasting mechanisms. PAHO is constantly seeking alternative sources of vaccines and adopting strategies to enable manufacturers to find new opportunities. In 2015, DCVM’s vaccines represented 74% of the total volume of 250 million doses procured through PAHO’s Revolving Fund.

Global Alliance for Vaccines and Immunization(GAVI) and Google’s contribution of USD 2 million, matched by the Bill & Melinda Gates Foundation’s funding to the GAVI Matching Fund, will be utilized to help countries to make evidence-based decisions on the purchase and maintenance of vaccine refrigerators. Innovators like Nexleaf Analytics, with support from private sector partners like Google, can help developing country governments make informed decisions to modernize the cold chain. Nexleaf’s use of innovative, low-cost sensor technology to support data-driven decision making is the kind of cutting-edge work needed to address big global challenges like vaccine delivery.

Public-private Partnerships (PPPs)

Multiple initiatives, Product Development Partnerships (PDPs) and PPPs are being taken up. PPPs imply a group of organizations that can better overcome market deficiencies than a single body. PPPs can circumvent barriers by spreading the risk of failure over multiple parties and projects. Most health PPPs have expert scientific boards from industry, academia and non-profit organizations that assist managers to choose research portfolios that align with the goals of the organization. The boards consider the cost and feasibility of projects to decide whether to pursue them.

United Nations Children’s Fund (UNICEF)

UNICEF supports the development of healthy markets through leveraging its procurement, transparency on pricing and building procurement capacity in countries. UNICEF is involved in the supply of pipeline vaccines, during outbreaks or health and humanitarian emergencies, and improving access to affordable new vaccines in middle-income countries (MICs). More than 50% of the total UNICEF procurement of $3.4 billion was dedicated to vaccines in 2015. A total of 2.8 billion doses of vaccines were procured by UNICEF, reaching 45% of the world’s children. 60% of the doses were sourced from DCVMs at a total value of $612 million, providing an important market opportunity for DCVMs.